key: cord-0842894-3yx36s4k
authors: Crescenzo-Chaigne, B.; Behillil, S.; Enouf, V.; Escriou, N.; Petres, S.; Ungeheuer, M. N.; Ghosn, J.; Tubiana, S.; Bouadma, L.; van der Werf, S.; Demeret, C.; group, French COVID cohort study
title: Nasopharyngeal and serological anti SARS-CoV-2 IgG/IgA responses in COVID-19 patients.
date: 2021-01-15
journal: nan
DOI: 10.1101/2021.01.13.20249038
sha: 26a1b8834893999b19a52f2f39d15d18fb5d922c
doc_id: 842894
cord_uid: 3yx36s4k

Background. The systemic antibody responses to SARS-CoV-2 in COVID-19 patients has been extensively studied. However, much less is known about the mucosal responses in the upper airways at the site of initial SARS-CoV-2 replication. Local antibody responses in the nasopharyngeal epithelium, that are likely to determine the course of infection, have not been analysed so far nor their correlation with antibody responses in serum. Methods. The IgG and IgA antibody responses were analysed in the plasma as well as in nasopharyngeal swabs (NPS) from the first four COVID-19 patients confirmed by RT-qPCR in France. Two were pauci-symptomatic while two developed severe disease. Taking advantage of a comprehensive series of plasma and nasopharyngeal samples, we characterized their antibody profiles from the second week post symptoms onset, by using an in-house ELISA to detect anti-SARS-CoV-2 Nucleoprotein (N) IgG and IgA. Results. Anti-N IgG and IgA antibodies were detected in the NPS of severe patients. Overall, the levels of IgA and IgG antibodies in plasma and NPS appeared specific to each patient. Conclusions. Anti-N IgG and IgA antibodies are detected in NPS, and their levels are related to antibody levels in plasma. The two patients with severe disease exhibited different antibody profiles that may reflect different disease outcome. For the pauci-symptomatic patients, one showed a low anti-N IgG and IgA response in the plasma only, while the other one did not exhibit overt serological response.

The Coronavirus disease 2019 (COVID-19) is a respiratory disease that has been threatening human health since early 2020, causing a global pandemic with dramatic social and economic consequences. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a highly transmissible and pathogenic coronavirus that emerged in late 2019 and has spread rapidly around the world during the year 2020 [1] . Considerable efforts are being made to understand SARS-CoV-2 epidemiology and pathogenesis, which is crucial for antiviral drug development and vaccine design [2, 3] .

Detecting SARS-CoV-2 RNAs by RT-qPCR from nasopharyngeal swabs (NPS) is a standard approach for COVID-19 diagnosis. A detailed characterization of the immune response to SARS-CoV-2 infection is mandatory, to understand its contribution to virus clearance and establishment of protection.

The first point of SARS-CoV-2 entry are the mucosal surfaces of the upper respiratory tract [4] .

Accordingly, characterization of the immune response in mucosal samples of infected patients, compared to the humoral response in plasma, is of interest. IgA have important roles in the immune response of mucosal surfaces [5] . Indeed, the antibody pool in the mucosa contains a higher proportion of IgA than in the plasma, and IgA may be important contributors to protection against viruses that target the mucosal surfaces [6] . IgA antibodies directed against SARS-CoV-2 are produced rapidly after infection and remain elevated in the serum for about one month after the onset of symptoms [7] [8] [9] [10] . The levels of IgA proved significantly higher in patients with severe compared to mild or moderate infection, following the same trend as anti SARS-CoV-2 IgG [7, 9] . Antibodies binding to the Receptor Binding Domain (RBD) of the Spike protein can neutralize SARS-CoV-2. Significantly, anti RBD IgA have been shown to have more potent neutralizing activities than IgG [11, 12] . However, the contribution of IgA in the mucosal antibody-mediated response to SARS-CoV-2 has not been reported. The mucosal response to SARS-CoV-2 has been assessed in the saliva of COVID-19 patients, while mucosal immunity in the NPS has not been characterized although it is the mucosal surface of the initial site of viral replication. Comparing anti-N IgA and IgG antibody levels of patient's NPS to their levels in plasma provides a more complete picture of the antibody-mediated immune response to SARS-CoV-2 infection.

In this study, we used an in-house ELISA [13] to detect IgG and IgA directed against the SARS-CoV-2 Nucleoprotein (N) in the NPS and in the plasma of four of the first recognized COVID-19 patients in France [14] . The patients experienced different clinical evolutions, two exhibiting severe disease and two mild and pauci-symptomatic disease. This set of patients is particularly valuable owing to (i) the different disease progression between patients; (ii) the extensive sampling over the COVID-19 illness period. It provides a unique opportunity to compare the systemic and mucosal antibody response in severe patients during the course of illness and in pauci-symptomatic individuals until and after their full recovery.

We detected IgG and IgA antibodies in the NPS of the two severe patients, demonstrating a mucosal antibody response to SARS-CoV-2. Serological and mucosal antibody profiles were specific to each patient, with higher antibody levels in the plasma of the severe patients as previously reported [15] [16] that were also reflected in the nasopharyngeal mucosa. Our study highlights a diversified humoral response to SARS-CoV-2 infection, with IgA to IgG ratios both in blood and NPS potentially underlying different disease outcome.

The objective of this study was to analyse the levels of anti-N SARS-CoV-2 IgA and IgG antibodies in the NPS and in the plasma of four confirmed COVID-19 cases with different clinical histories. We used an anti-N ELISA, the performance of which was evaluated using NPS and serum from pre-epidemic individuals.

Cohorts. Pre-epidemic NPS originated from the National Reference Center (NRC) for respiratory viruses and were confirmed to be SARS-CoV-2 negative by RT-PCR (data not shown). Pre-epidemic sera were provided by the ICAReB platform (Clinical Investigation and Access to Research Bioresources, Institut Pasteur) or the Center for translational Science, Institut Pasteur. All pre-epidemic samples were collected before November 2019. Samples from donors were collected in accordance with local ethical guidelines by Pasteur Institute.

The NPS and plasma samples for the four COVID-19 patients are part of patients included in one of the participating center (i.e., Hôpital Bichat, APHP, Paris, France) of the French COVID cohort assessing hospitalized patients with a virologically-confirmed COVID-19 (NCT04262921) [17] . This study was conducted with the understanding and the consent of each participant or its surrogate. Ethics approval was obtained from the French Ethic Committee CPP-Ile-de-France VI (ID-RCB: 2020-A00256-33). NPS and plasma or sera were heatinactivated 30 min at 56°C is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.13.20249038 doi: medRxiv preprint ELISA-N. The ELISA test was performed as described in Grzelak et al [13] . Briefly, 96-well ELISA plates were coated overnight with 50 ng of purified bacterially expressed N protein of SARS-CoV-2 in PBS. After washing 3 times with PBS-0.1% Tween 20 (PBST), 200µl of PBST-3% milk were added and incubated 1 h at 37°C. After washing, 100 µl of diluted plasma or NPS in PBST-3% milk were added and incubated 1 h at 37°C. After washing, plates were incubated with 5,000 or 4,000-fold diluted peroxidase-conjugated goat anti human IgG or IgA respectively (#2040-05 and #2050-05 -Southern Biotech) for 1h. Plates were revealed by adding 100 µl of HRP chromogenic substrate (TMB, Eurobio Scientific) after 3 washing steps in PBST.

After 10 min incubation, the reaction was stopped by adding 1M H3PO4 and optical densities were measured at 450 nm (OD 450). All tests were performed in triplicate. The patients were admitted at Hospital Bichat, Paris, and confirmed for SARS-CoV-2 infection by RT-PCR at the time of admission. They experienced different clinical evolutions: two exhibited severe disease, one being fatal, and two had mild disease [14] . Three to eight NPS samples collected between days 10 and 24 post symptoms onset (PSO), and five to nine blood samples collected between days 10 and 32 PSO, including dates matching the NPS, were used to explore the IgG and IgA anti-N response of each of the patient. Clinical history and sampling periods are summarized in Table 1 .

We previously developed an anti-N ELISA test to assess antibody level in plasma or sera [13] .

In this study, we adapted this ELISA to the detection of anti-N antibodies in the NPS, and used it to compare the production of antibodies in the plasma and in the NPS. Serial 2-fold dilutions of the samples were assessed for anti-N IgG and IgA antibodies, using anti IgG and anti IgA is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.13.20249038 doi: medRxiv preprint Patient 5 did not show any significant seroconversion to SARS-CoV-2 N protein, despite development of mild symptoms and confirmation of infection by RT-PCR [14] . For this patient IgG antibodies were only detected at a titer above the cut off value at day 23 PSO (Figure 3 ), after discharge from the hospital and full recovery.

Since, unlike plasma, the amount of biological material recovered in NPS and placed in liquid transport medium is not constant from one sample to another, we compared the IgG and IgA levels within each NPS sample, but did not perform day-by-day nor patient-to-patient comparisons. IgG and IgA ELISA signals above the cut-off were detected in NPS of patients is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.13.20249038 doi: medRxiv preprint patient 3, who suffered an active viral replication until the fatal outcome of his disease, these results suggest that serological IgA antibodies are not the main drivers of disease resolution.

We could also detect IgG and IgA in the NPS of these severe patients, indicating the occurrence of a humoral response at the initial site of infection, the nasopharyngeal mucosa. The IgA levels in NPS were consistently lower than IgG just as in plasma, suggesting that the mucosal response was dominated by an IgG response at late times of infection. This differs from the mucosal response that has been detected in COVID-19 patient's saliva earlier post infection, where higher proportions of IgA were detected [19] . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. [21] , or whether this patient belongs to the small fraction of pauci-symptomatic patients defined as "IgG non-responders" [15] . We extend here these observations to the IgA serological response, and show herein that patient 5 did not either develop any detectable mucosal humoral response. The fact that some pauci-symptomatic patients may not develop any humoral response neither in the nasal mucosa nor in serum, should be taken into account in seroprevalence surveys. It also suggests that non-humoral, innate or cell-mediated immunity may be sufficient to resolve infection as previously reported [22] . Table 1 -Summary of sampling dates along with patient's illness history. The data are from (14) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.13.20249038 doi: medRxiv preprint control sera are in grey, the filled light grey area shows ELISA signals generated by negative serum samples.

the IgG and IgA reactivity in the NPS for each patient (p1, 3, 4, 5) . Graphs show the optical density units at 450 nm (Y axis) and reciprocal plasma dilutions (X axis) of each sample, taken at different times PSO, as described in Table 1 . Dilutions of pre-epidemic control NPS are in grey, the filled light grey area shows ELISA signals generated by negative NPS samples. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint taken at different times PSO, as described in Table 1 . Dilutions of pre-epidemic control sera are in grey, the filled light grey area shows ELISA signals generated by negative serum samples. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.13.20249038 doi: medRxiv preprint

The French Covid Cohort is funded through the Ministry of Health and Social Affairs (PHRC n°20-0424) and Ministry of Higher Education and Research dedicated COVID19 fund. Funding sources are not involved in the study design, data acquisition, data analysis, data interpretation or manuscript writing. List of the membership of the French COVID cohort study group : Mélanie RORIZ

Hôpital privé d'Antony)

Antoine MERCKX (CH de Cahors)

Simon BESSIS (Hôpital Raymond Poincaré, Garches)

Stanislas REBAUDET (Hôpital Européen de Marseille)

Christophe RAPP (Hôpital Américain de Paris, Neuilly sur Seine)

Younes KERROUMI, Vanina MEYSSONNIER (Groupe Hospitalier Diacon-esses

Hu-gues AUMAÎTRE (CH de Perpignan)

Ali HACHEMI (CH Soisson)

Characteristics of SARS-CoV-2 and COVID-19

SARS-CoV-2 vaccines in development

Therapeutic Development and Drugs for the Treatment of COVID-19

A Novel Coronavirus from Patients with Pneumonia in China

The immune geography of IgA induction and function

Rethinking mucosal antibody responses: IgM, IgG and IgD join IgA

Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients

Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)

Serum IgA, IgM, and IgG responses in COVID-19

Humoral Immune Responses in COVID-19

Patients: A Window on the State of the Art

Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro

IgA dominates the early neutralizing antibody response to SARS-CoV-2

A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations

Clinical and virological data of the first cases of COVID-19 in Europe: a case series

Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders

Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019

Impact on disease mortality of clinical, biological, and virological characteristics at hospital admission and overtime in COVID-19 patients

Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset

Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients

Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Induces Cellular Immune Response without Seroconversion